Health

Scientists Fear 'Female Viagra' Works Too Well

| by Sarah Fruchtnicht
article imagearticle image

While clinical trials for the female libido-boosting pill “Lybrido” are going well, New York Times writer Daniel Bergner reported researchers still worry that an effective desire-pill could turn “women into nymphomaniacs.”

Nicknamed the “female Viagra,” Bergner said there is concern the Food and Drug Administration would reject this drug over fears it would be “creating the sexually aggressive woman.”

“More than one adviser to the industry told me that companies worried about the prospect that their study results would be too strong, that the FDA would reject an application out of concern that a chemical would lead to female excesses, crazed binges of infidelity, societal splintering,” Bergner wrote.

Women who participate in the Lybrido study aren’t just focused on improving relationships. Many have a sense of personal longing to get their groove back.

Popular Video

This judge looked an inmate square in the eyes and did something that left the entire courtroom in tears:

“To frame this merely in terms of improving marriages is to talk the talk of Victorianism and, in a sense, of evolutionary psychology, ways of thinking that diminish the importance of sex to women,” Bergner said in an interview with Rachel Nolan.

Drug companies will be keen on tempering the potency of passion-stimulants for females.

“You want your effects to be good but not too good,” Andrew Goldstein, who is conducting the study in Washington, told Bergner. “There was a lot of discussion about it by the experts in the room … the need to show that you’re not turning women into nymphomaniacs. There’s a bias against — a fear of creating the sexually aggressive woman.”

Bergner said the concerns over the drug working too well surprised him, but that, “Despite all the wackiness, most of the scientists I spent time with got into this research because they recognize sexual desire as absolutely central to the psyche. “

Sources: SFGate.com, NY Times